Myelodysplastic syndromes, version 2.2017: Clinical practice guidelines in oncology

Peter L. Greenberg, Richard M. Stone, Aref Al-Kali, Stefan K. Barta, Rafael Bejar, John M. Bennett, Hetty Carraway, Carlos M. De Castro, H. Joachim Deeg, Amy E. DeZern, Amir T. Fathi, Olga Frankfurt, Karin Gaensler, Guillermo Garcia-Manero, Elizabeth A. Griffiths, David Head, Ruth Horsfall, Robert A. Johnson, Mark Juckett, Virginia M. KlimekRami Komrokji, Lisa A. Kujawski, Lori J Maness-Harris, Margaret R. O'Donnell, Daniel A. Pollyea, Paul J. Shami, Brady L. Stein, Alison R. Walker, Peter Westervelt, Amer Zeidan, Dorothy A. Shead, Courtney Smith

Research output: Contribution to journalReview article

87 Citations (Scopus)

Abstract

The myelodysplastic syndromes (MDS) comprise a heterogenous group of myeloid disorders with a highly variable disease course. Diagnostic criteria to better stratify patients with MDS continue to evolve, based on morphology, cytogenetics, and the presence of cytopenias. More accurate classification of patients will allow for better treatment guidance. Treatment encompasses supportive care, treatment of anemia, lowintensity therapy, and high-intensity therapy. This portion of the guidelines focuses on diagnostic classification, molecular abnormalities, therapeutic options, and recommended treatment approaches.

Original languageEnglish (US)
Pages (from-to)60-87
Number of pages28
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume15
Issue number1
DOIs
StatePublished - Jan 1 2017

Fingerprint

Myelodysplastic Syndromes
Practice Guidelines
Therapeutics
Molecular Pathology
Cytogenetics
Anemia
Guidelines

ASJC Scopus subject areas

  • Oncology

Cite this

Greenberg, P. L., Stone, R. M., Al-Kali, A., Barta, S. K., Bejar, R., Bennett, J. M., ... Smith, C. (2017). Myelodysplastic syndromes, version 2.2017: Clinical practice guidelines in oncology. JNCCN Journal of the National Comprehensive Cancer Network, 15(1), 60-87. https://doi.org/10.6004/jnccn.2017.0007

Myelodysplastic syndromes, version 2.2017 : Clinical practice guidelines in oncology. / Greenberg, Peter L.; Stone, Richard M.; Al-Kali, Aref; Barta, Stefan K.; Bejar, Rafael; Bennett, John M.; Carraway, Hetty; De Castro, Carlos M.; Deeg, H. Joachim; DeZern, Amy E.; Fathi, Amir T.; Frankfurt, Olga; Gaensler, Karin; Garcia-Manero, Guillermo; Griffiths, Elizabeth A.; Head, David; Horsfall, Ruth; Johnson, Robert A.; Juckett, Mark; Klimek, Virginia M.; Komrokji, Rami; Kujawski, Lisa A.; Maness-Harris, Lori J; O'Donnell, Margaret R.; Pollyea, Daniel A.; Shami, Paul J.; Stein, Brady L.; Walker, Alison R.; Westervelt, Peter; Zeidan, Amer; Shead, Dorothy A.; Smith, Courtney.

In: JNCCN Journal of the National Comprehensive Cancer Network, Vol. 15, No. 1, 01.01.2017, p. 60-87.

Research output: Contribution to journalReview article

Greenberg, PL, Stone, RM, Al-Kali, A, Barta, SK, Bejar, R, Bennett, JM, Carraway, H, De Castro, CM, Deeg, HJ, DeZern, AE, Fathi, AT, Frankfurt, O, Gaensler, K, Garcia-Manero, G, Griffiths, EA, Head, D, Horsfall, R, Johnson, RA, Juckett, M, Klimek, VM, Komrokji, R, Kujawski, LA, Maness-Harris, LJ, O'Donnell, MR, Pollyea, DA, Shami, PJ, Stein, BL, Walker, AR, Westervelt, P, Zeidan, A, Shead, DA & Smith, C 2017, 'Myelodysplastic syndromes, version 2.2017: Clinical practice guidelines in oncology', JNCCN Journal of the National Comprehensive Cancer Network, vol. 15, no. 1, pp. 60-87. https://doi.org/10.6004/jnccn.2017.0007
Greenberg, Peter L. ; Stone, Richard M. ; Al-Kali, Aref ; Barta, Stefan K. ; Bejar, Rafael ; Bennett, John M. ; Carraway, Hetty ; De Castro, Carlos M. ; Deeg, H. Joachim ; DeZern, Amy E. ; Fathi, Amir T. ; Frankfurt, Olga ; Gaensler, Karin ; Garcia-Manero, Guillermo ; Griffiths, Elizabeth A. ; Head, David ; Horsfall, Ruth ; Johnson, Robert A. ; Juckett, Mark ; Klimek, Virginia M. ; Komrokji, Rami ; Kujawski, Lisa A. ; Maness-Harris, Lori J ; O'Donnell, Margaret R. ; Pollyea, Daniel A. ; Shami, Paul J. ; Stein, Brady L. ; Walker, Alison R. ; Westervelt, Peter ; Zeidan, Amer ; Shead, Dorothy A. ; Smith, Courtney. / Myelodysplastic syndromes, version 2.2017 : Clinical practice guidelines in oncology. In: JNCCN Journal of the National Comprehensive Cancer Network. 2017 ; Vol. 15, No. 1. pp. 60-87.
@article{bfaa9b57485f4103a619bfb6fc3941ba,
title = "Myelodysplastic syndromes, version 2.2017: Clinical practice guidelines in oncology",
abstract = "The myelodysplastic syndromes (MDS) comprise a heterogenous group of myeloid disorders with a highly variable disease course. Diagnostic criteria to better stratify patients with MDS continue to evolve, based on morphology, cytogenetics, and the presence of cytopenias. More accurate classification of patients will allow for better treatment guidance. Treatment encompasses supportive care, treatment of anemia, lowintensity therapy, and high-intensity therapy. This portion of the guidelines focuses on diagnostic classification, molecular abnormalities, therapeutic options, and recommended treatment approaches.",
author = "Greenberg, {Peter L.} and Stone, {Richard M.} and Aref Al-Kali and Barta, {Stefan K.} and Rafael Bejar and Bennett, {John M.} and Hetty Carraway and {De Castro}, {Carlos M.} and Deeg, {H. Joachim} and DeZern, {Amy E.} and Fathi, {Amir T.} and Olga Frankfurt and Karin Gaensler and Guillermo Garcia-Manero and Griffiths, {Elizabeth A.} and David Head and Ruth Horsfall and Johnson, {Robert A.} and Mark Juckett and Klimek, {Virginia M.} and Rami Komrokji and Kujawski, {Lisa A.} and Maness-Harris, {Lori J} and O'Donnell, {Margaret R.} and Pollyea, {Daniel A.} and Shami, {Paul J.} and Stein, {Brady L.} and Walker, {Alison R.} and Peter Westervelt and Amer Zeidan and Shead, {Dorothy A.} and Courtney Smith",
year = "2017",
month = "1",
day = "1",
doi = "10.6004/jnccn.2017.0007",
language = "English (US)",
volume = "15",
pages = "60--87",
journal = "JNCCN Journal of the National Comprehensive Cancer Network",
issn = "1540-1405",
publisher = "Cold Spring Publishing LLC",
number = "1",

}

TY - JOUR

T1 - Myelodysplastic syndromes, version 2.2017

T2 - Clinical practice guidelines in oncology

AU - Greenberg, Peter L.

AU - Stone, Richard M.

AU - Al-Kali, Aref

AU - Barta, Stefan K.

AU - Bejar, Rafael

AU - Bennett, John M.

AU - Carraway, Hetty

AU - De Castro, Carlos M.

AU - Deeg, H. Joachim

AU - DeZern, Amy E.

AU - Fathi, Amir T.

AU - Frankfurt, Olga

AU - Gaensler, Karin

AU - Garcia-Manero, Guillermo

AU - Griffiths, Elizabeth A.

AU - Head, David

AU - Horsfall, Ruth

AU - Johnson, Robert A.

AU - Juckett, Mark

AU - Klimek, Virginia M.

AU - Komrokji, Rami

AU - Kujawski, Lisa A.

AU - Maness-Harris, Lori J

AU - O'Donnell, Margaret R.

AU - Pollyea, Daniel A.

AU - Shami, Paul J.

AU - Stein, Brady L.

AU - Walker, Alison R.

AU - Westervelt, Peter

AU - Zeidan, Amer

AU - Shead, Dorothy A.

AU - Smith, Courtney

PY - 2017/1/1

Y1 - 2017/1/1

N2 - The myelodysplastic syndromes (MDS) comprise a heterogenous group of myeloid disorders with a highly variable disease course. Diagnostic criteria to better stratify patients with MDS continue to evolve, based on morphology, cytogenetics, and the presence of cytopenias. More accurate classification of patients will allow for better treatment guidance. Treatment encompasses supportive care, treatment of anemia, lowintensity therapy, and high-intensity therapy. This portion of the guidelines focuses on diagnostic classification, molecular abnormalities, therapeutic options, and recommended treatment approaches.

AB - The myelodysplastic syndromes (MDS) comprise a heterogenous group of myeloid disorders with a highly variable disease course. Diagnostic criteria to better stratify patients with MDS continue to evolve, based on morphology, cytogenetics, and the presence of cytopenias. More accurate classification of patients will allow for better treatment guidance. Treatment encompasses supportive care, treatment of anemia, lowintensity therapy, and high-intensity therapy. This portion of the guidelines focuses on diagnostic classification, molecular abnormalities, therapeutic options, and recommended treatment approaches.

UR - http://www.scopus.com/inward/record.url?scp=85009133609&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85009133609&partnerID=8YFLogxK

U2 - 10.6004/jnccn.2017.0007

DO - 10.6004/jnccn.2017.0007

M3 - Review article

C2 - 28040720

AN - SCOPUS:85009133609

VL - 15

SP - 60

EP - 87

JO - JNCCN Journal of the National Comprehensive Cancer Network

JF - JNCCN Journal of the National Comprehensive Cancer Network

SN - 1540-1405

IS - 1

ER -